Compare Cytokinetics Inc (CYTK) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs National Beverage Corp. — how do they compare? Cytokinetics Inc trades at $62.74 (market cap $8.62B), while National Beverage Corp. trades at $30.35 (market cap $2.89B). The key difference: Cytokinetics Inc is far larger — about 3× National Beverage Corp.'s market cap, and Cytokinetics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and National Beverage Corp. for 33 Days on average.
| CYTK | FIZZ | |
|---|---|---|
Market Cap | $8.62B | $2.89B |
Volume | 2,594,626 | 553,950 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $37.73 |
52-Week Low | $54.76 | $29.20 |
Typical Hold Time | 19 Days | 33 Days |
Enterprise Value | $8.72B | $2.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
FIZZ trades at $30.58, up 3.31% today, but faces bearish technical signals with recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margins improved to 15.55% in 2025. The company maintains strong profitability with 40.13% ROE but faces margin pressure from input costs. A $3.25 special dividend payment in July 2026 reduced shareholder equity significantly.
Outlook remains challenging with analyst consensus leaning bearish (50% sell ratings). While valuation appears reasonable (P/E 16.58), stagnant growth and consecutive earnings misses pose headwinds. The key opportunity lies in potential revenue recovery, but investors face risks from competitive pressures and ongoing margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
